Literature DB >> 27249993

Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy.

Angelika Schìtz1, Stephan Moser2, Katharina Marchart1, Hans Haltmayer1, Michael Gschwantler2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27249993     DOI： 10.1038/ajg.2016.119

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  5 in total

Review 1.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Authors:  Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt
Journal:  Lancet       Date:  2011-07-27       Impact factor: 79.321

2.  Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial.

Authors:  Karina M Berg; Alain Litwin; Xuan Li; Moonseong Heo; Julia H Arnsten
Journal:  Drug Alcohol Depend       Date:  2010-09-15       Impact factor: 4.492

3.  Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010.

Authors:  L Wiessing; G Likatavicius; D Hedrich; B Guarita; M J van de Laar; J Vicente
Journal:  Euro Surveill       Date:  2011-12-01

4.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

Authors:  Kris V Kowdley; Stuart C Gordon; K Rajender Reddy; Lorenzo Rossaro; David E Bernstein; Eric Lawitz; Mitchell L Shiffman; Eugene Schiff; Reem Ghalib; Michael Ryan; Vinod Rustgi; Mario Chojkier; Robert Herring; Adrian M Di Bisceglie; Paul J Pockros; G Mani Subramanian; Di An; Evguenia Svarovskaia; Robert H Hyland; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; David Pound; Michael W Fried
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

5.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

Authors:  Mark S Sulkowski; David F Gardiner; Maribel Rodriguez-Torres; K Rajender Reddy; Tarek Hassanein; Ira Jacobson; Eric Lawitz; Anna S Lok; Federico Hinestrosa; Paul J Thuluvath; Howard Schwartz; David R Nelson; Gregory T Everson; Timothy Eley; Megan Wind-Rotolo; Shu-Pang Huang; Min Gao; Dennis Hernandez; Fiona McPhee; Diane Sherman; Robert Hindes; William Symonds; Claudio Pasquinelli; Dennis M Grasela
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245
  5 in total
  14 in total

Review 1.  Direct-acting antiviral agents for HCV infection affecting people who inject drugs.

Authors:  Jason Grebely; Behzad Hajarizadeh; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-23       Impact factor: 46.802

Review 2.  Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.

Authors:  Emma Day; Margaret Hellard; Carla Treloar; Julie Bruneau; Natasha K Martin; Anne Øvrehus; Olav Dalgard; Andrew Lloyd; John Dillon; Matt Hickman; Jude Byrne; Alain Litwin; Mojca Maticic; Philip Bruggmann; Havard Midgard; Brianna Norton; Stacey Trooskin; Jeffrey V Lazarus; Jason Grebely
Journal:  Liver Int       Date:  2018-09-22       Impact factor: 5.828

3.  Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.

Authors:  Eshan U Patel; Sunil S Solomon; Allison M Mcfall; Aylur K Srikrishnan; Amrose Pradeep; Paneerselvam Nandagopal; Oliver Laeyendecker; Aaron A R Tobian; David L Thomas; Mark S Sulkowski; M Suresh Kumar; Shruti H Mehta
Journal:  Int J Drug Policy       Date:  2018-04-19

Review 4.  HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.

Authors:  Marianne Martinello; Behzad Hajarizadeh; Jason Grebely; Gregory J Dore; Gail V Matthews
Journal:  Curr HIV/AIDS Rep       Date:  2017-06       Impact factor: 5.071

5.  Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study.

Authors:  Michael Gschwantler; Hermann Laferl; Wolfgang Vogel; Wolfgang Korak; Stephan Moser; Harald Hofer; Bernhard Bauer; Michael Schleicher; Barbara Bognar; Martin Bischof; Rudolf Stauber; Andreas Maieron; Peter Ferenci
Journal:  Wien Klin Wochenschr       Date:  2017-09-12       Impact factor: 1.704

Review 6.  Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.

Authors:  Brianna L Norton; Matthew J Akiyama; Philippe J Zamor; Alain H Litwin
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

7.  Nurse case management to improve the hepatitis C care continuum in HIV co-infection: Results of a randomized controlled trial.

Authors:  Laura E Starbird; Chakra Budhathoki; Hae-Ra Han; Mark S Sulkowski; Nancy R Reynolds; Jason E Farley
Journal:  J Viral Hepat       Date:  2019-12-09       Impact factor: 3.728

8.  Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients.

Authors:  David Chromy; Philipp Schwabl; Theresa Bucsics; Bernhard Scheiner; Robert Strassl; Florian Mayer; Maximilian C Aichelburg; Katharina Grabmeier-Pfistershammer; Michael Trauner; Markus Peck-Radosavljevic; Thomas Reiberger; Mattias Mandorfer
Journal:  Wien Klin Wochenschr       Date:  2017-07-25       Impact factor: 1.704

9.  Hepatitis C in injection drug users: It is time to treat.

Authors:  Alberto Grassi; Giorgio Ballardini
Journal:  World J Gastroenterol       Date:  2017-05-28       Impact factor: 5.742

10.  Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?

Authors:  Jason Grebely; Gregory J Dore; Sébastien Morin; Jürgen K Rockstroh; Marina B Klein
Journal:  J Int AIDS Soc       Date:  2017-07-28       Impact factor: 5.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.